Clinical Report: MASLD During Pregnancy Triples Preterm Birth Risk
Overview
Women with metabolic dysfunction–associated steatotic liver disease (MASLD) face a significantly increased risk of preterm birth and cesarean delivery. Research indicates that MASLD is associated with an adjusted odds ratio of 3.41 for preterm birth compared to women without liver disease.
Background
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a condition that can lead to various complications during pregnancy. Understanding the implications of MASLD on pregnancy outcomes is crucial for managing the health of both the mother and the infant.
Data Highlights
| Outcome | MASLD Group | Comparator Group | Adjusted Odds Ratio (95% CI) |
|---|---|---|---|
| Preterm Birth (< 37 weeks) | 16.7% | 4.7% | 3.41 (1.98–5.88) |
| Medically Indicated Preterm Birth | N/A | N/A | 11.90 (2.46–57.59) |
| Spontaneous Preterm Birth | N/A | N/A | 2.42 (1.16–5.04) |
| C-section Rate | 32.1% | 16.0% | 1.63 (1.17–2.27) |
| Low Birth Weight (< 2,500 g) | N/A | N/A | 2.66 (1.35–5.24) |
Key Findings
- Preterm delivery occurred in 16.7% of MASLD pregnancies compared to 4.7% in the control group.
- MASLD was associated with an adjusted odds ratio of 3.41 for preterm birth after adjusting for confounding factors.
- The risk of medically indicated preterm births was significantly higher in the MASLD group (adjusted OR = 11.90).
- C-section rates were higher in the MASLD group at 32.1%, compared to 16.0% in the control group.
- Low birth weight was more common among infants born to women with MASLD (adjusted OR = 2.66).
- The severity of liver disease did not correlate with a higher risk of preterm birth.
Clinical Implications
Healthcare providers should be aware of the increased risks associated with MASLD during pregnancy, particularly regarding preterm birth and cesarean delivery.
Conclusion
The findings indicate that MASLD may independently contribute to adverse pregnancy outcomes.
Related Resources & Content
- Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study - PMC, 2023
- Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD
- conexiant — Fetal Growth Extremes Linked to MS Risk
- conexiant — Early TMP-SMX Use Linked to Birth Defects
- The Journal of Clinical Endocrinology & Metabolism — Link Between Reduced Maternal Sleep Duration and Neurodevelopmental Delays in Children: Findings from a Prospective Cohort Study
- BMC Pregnancy and Childbirth — Association of maternal multiple serum metal/metalloid concentrations and metabolic gene polymorphisms with offspring skeletal defects: a multicenter case-control study
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Pregnancy: A Review - PubMed
- Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD
- Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
